Affymetrix Inc. Sets New 1-Year High at $8.05 (AFFX)
Affymetrix (NASDAQ:AFFX)’s share price reached a new 52-week high during mid-day trading on Monday, American Banking News reports. The stock traded as high as $8.05 and last traded at $7.87, with a volume of 3,175,070 shares traded. The stock had previously closed at $7.31.
AFFX has been the subject of a number of recent research reports. Analysts at UBS AG raised their price target on shares of Affymetrix from $4.00 to $7.00 in a research note to investors on Thursday. They now have a “neutral” rating on the stock. Separately, analysts at Mizuho raised their price target on shares of Affymetrix from $8.00 to $10.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Thomson Reuters/Verus upgraded shares of Affymetrix from a “hold” rating to a “buy” rating in a research note to investors on Monday, October 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $7.10.
Affymetrix has a 52 week low of $2.96 and a 52 week high of $7.37. The stock has a 50-day moving average of $6.55 and a 200-day moving average of $4.89. The company’s market cap is $564.9 million.
Affymetrix (NASDAQ:AFFX) last released its earnings data on Wednesday, October 30th. The company reported $0.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.02 by $0.03. The company had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.95 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was up 1.0% on a year-over-year basis. On average, analysts predict that Affymetrix will post $0.11 earnings per share for the current fiscal year.
Affymetrix, Inc (NASDAQ:AFFX) is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.